Form 4: Tarsus Pharmaceuticals' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, was granted stock options and restricted stock units (RSUs) in connection with her appointment.

Summary

• Elizabeth Yeu Lin, the Chief Medical Officer of Tarsus Pharmaceuticals, received stock options and restricted stock units on November 4, 2024.
• The stock options grant consists of 41,074 options with an exercise price of $46.21, exercisable starting November 3, 2024, and expiring on November 3, 2034.
• Additionally, she received 27,278 restricted stock units (RSUs), each representing a contingent right to receive one share of Tarsus Pharmaceuticals' common stock.
• These grants were disclosed in a Form 8-K filed on November 5, 2024, in connection with her appointment as Chief Medical Officer.

Sentiment

Score: 7

Explanation: The document simply reports the grant of stock options and RSUs to a key executive, which is a standard practice. It suggests confidence in the company's future, but doesn't contain any groundbreaking news.

Positives

• The grant of stock options and RSUs to the Chief Medical Officer aligns her interests with those of the shareholders.
• The vesting schedule of the options and RSUs may incentivize long-term performance and retention.

Industry Context

Grants of stock options and RSUs are common practice for incentivizing and retaining key executives in the pharmaceutical industry.

Management Changes

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it aligns management's interests with theirs.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates